Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SFT-601
- Development stage
- Preclinical
- Lead developer
- invoX Pharma
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
SFT-601 is an investigational inhaled drug formulation being developed by invoX Pharma for the treatment of chronic obstructive pulmonary disease (COPD). The therapy is designed for delivery via the Softhaler® platform, a proprietary propellant-free, multi-dose dry powder inhaler (DPI) technology intended to optimize pulmonary drug deposition and patient ease of use. As of early 2024, SFT-601 is in the early stages of development (preclinical or early clinical), and its specific active pharmaceutical ingredient and molecular mechanism of action have not been publicly disclosed by the developer.
- Other names
- SFT-601-IVOXSFT601-IVOXSFT 601-IVOX
Beyond the preview
Go deeper on SFT-601.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SFT-601.